What does the new FDA approval of the tucatinib combo mean for HER2-positive breast cancer patients?
The tucatinib maintenance combination extended median progression-free survival in HER2CLIMB-05, while overall-survival data remain immature.
On Oct. 7, the FDA approved tucatinib (Tukysa) with trastuzumab and pertuzumab as maintenance treatment for adults with unresectable locally advanced or metastatic HER2-positive breast cancer after induction therapy. The distinction matters: induction uses intensive treatment to shrink or stabilize the cancer; maintenance then aims to hold that control for longer.
In the 654-patient HER2CLIMB-05 trial, median progression-free survival was 24.9 months with tucatinib versus 16.3 months with the placebo combination, a hazard ratio of 0.64 (p<0.0001). Tucatinib is an oral 300 mg pill taken twice daily, which can be more convenient than adding another infusion, but convenience does not erase risk. Overall-survival data are not mature, and the prescribing information carries a boxed warning for liver toxicity, so liver tests and specialist monitoring matter.
The approval extends the average time before progression; it does not establish a cure, and treatment choices belong in a patient’s oncology discussion.
Ask AI about this tip
Send this tip to your favorite AI assistant for a plain-language walkthrough, follow-up questions, or help applying it to your device.